Negative Regulation of EGFR-Vav2 Signaling Axis by Cbl Ubiquitin Ligase Controls EGF Receptor-mediated Epithelial Cell Adherens Junction Dynamics and Cell Migration

被引:36
作者
Duan, Lei [2 ,6 ]
Raja, Srikumar M. [2 ,6 ]
Chen, Gengsheng [6 ]
Virmani, Sumeet [6 ]
Williams, Stetson H. [2 ]
Clubb, Robert J. [2 ]
Mukhopadhyay, Chandrani [2 ]
Rainey, Mark A. [2 ,6 ]
Ying, Guoguang [6 ]
Dimri, Manjari [6 ]
Chen, Jing [6 ]
Reddi, Alagarsamy L. [6 ]
Naramura, Mayumi [2 ,6 ]
Band, Vimla [2 ,5 ,6 ]
Band, Hamid [1 ,2 ,3 ,4 ,6 ]
机构
[1] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Pharmacol & Neurosci, Omaha, NE 68198 USA
[5] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Coll Med, Omaha, NE 68198 USA
[6] Northwestern Univ, Dept Med, N Shore Univ Hlth Syst, Evanston, IL 60201 USA
基金
美国国家卫生研究院;
关键词
GROWTH-FACTOR-RECEPTOR; NUCLEOTIDE-EXCHANGE FACTORS; RHO-FAMILY GTPASES; C-CBL; TUMOR PROGRESSION; TYROSINE KINASES; DOWN-REGULATION; E-CADHERIN; BREAST-CANCER; VAV PROTEINS;
D O I
10.1074/jbc.M110.188086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The E3 ubiquitin ligase Casitas B lymphoma protein (Cbl) controls the ubiquitin-dependent degradation of EGF receptor (EGFR), but its role in regulating downstream signaling elements with which it associates and its impact on biological outcomes of EGFR signaling are less clear. Here, we demonstrate that stimulation of EGFR on human mammary epithelial cells disrupts adherens junctions (AJs) through Vav2 and Rac1/Cdc42 activation. In EGF-stimulated cells, Cbl regulates the levels of phosphorylated Vav2 thereby attenuating Rac1/Cdc42 activity. Knockdown of Cbl and Cbl-b enhanced the EGF-induced disruption of AJs and cell motility. Overexpression of constitutively active Vav2 activated Rac1/Cdc42 and reorganized junctional actin cytoskeleton; these effects were suppressed by WT Cbl and enhanced by a ubiquitin ligase-deficient Cbl mutant. Cbl forms a complex with phospho-EGFR and phospho-Vav2 and facilitates phospho-Vav2 ubiquitinylation. Cbl can also interact with Vav2 directly in a Cbl Tyr-700-dependent manner. A ubiquitin ligase-deficient Cbl mutant enhanced the morphological transformation of mammary epithelial cells induced by constitutively active Vav2; this effect requires an intact Cbl Tyr-700. These results indicate that Cbl ubiquitin ligase plays a critical role in the maintenance of AJs and suppression of cell migration through down-regulation of EGFR-Vav2 signaling.
引用
收藏
页码:620 / 633
页数:14
相关论文
共 85 条
[1]
Vav2 is an activator of Cdc42, Rac1, and RhoA [J].
Abe, K ;
Rossman, KL ;
Liu, B ;
Ritola, KD ;
Chiang, D ;
Campbell, SL ;
Burridge, K ;
Der, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (14) :10141-10149
[2]
[Anonymous], CIBA FDN S
[3]
[Anonymous], CIBA FDN S
[4]
Targeting HERI/EGFR: A molecular approach to cancer therapy [J].
Arteaga, C .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :3-14
[5]
Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016
[6]
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies [J].
Bacher, Ulrike ;
Haferlach, Claudia ;
Schnittger, Susanne ;
Kohlmann, Alexander ;
Kern, Wolfgang ;
Haferlach, Torsten .
ANNALS OF HEMATOLOGY, 2010, 89 (07) :643-652
[7]
DISTINCTIVE TRAITS OF NORMAL AND TUMOR-DERIVED HUMAN MAMMARY EPITHELIAL-CELLS EXPRESSED IN A MEDIUM THAT SUPPORTS LONG-TERM GROWTH OF BOTH CELL-TYPES [J].
BAND, V ;
SAGER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) :1249-1253
[8]
Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors [J].
Bao, J ;
Gur, G ;
Yarden, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2438-2443
[9]
THE ROLE OF CELL-ADHESION MOLECULES IN CANCER INVASION AND METASTASIS [J].
BEHRENS, J .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 24 (03) :175-184
[10]
BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124